Omnihealth Practice

CARDIOLOGY

More than glycated hemoglobin: Dapagliflozin preserves cardiorenal functions in patients with type 2 diabetes mellitus

21 Sep 2021

Breaking the vicious cycle of cardiac, renal and metabolic risks in patients at risk of chronic kidney disease

13 Jul 2021

Dapagliflozin as a treatment reduces worsening heart failure and cardiovascular death among heart failure patients

28 Feb 2021

Evolocumab greatly reduces low-density lipoprotein cholesterol levels in familial hypercholesterolemia: A local case review

30 Oct 2020

Prolonged use of DAPT with ticagrelor in a high-risk post-myocardial infarction patient: A local case report

01 Sep 2020

A case of patient with recurrent cardiovascular events stabilized by evolocumab in Hong Kong

29 Jun 2020

Evolocumab lowers lipoprotein(a) levels in triple-vessel coronary artery disease: A local case report

29 Apr 2020

A case review on cardiac risk stratification in the secondary prevention of cardiovascular diseases

28 Feb 2020

Overcoming the challenging journey: Secondary prevention of CV events with PCSK9i

30 Oct 2019

Self-care is the key in the management of chronic heart failure

31 Oct 2019

Self-care is the key in the management of chronic heart failure

Heart failure (HF) is a commonly occurring disease affecting numerous patients worldwide. The rates of new HF hospitalization among the Chinese population in Hong Kong between 2005 and 2012 were 0.59 in every 1,000 males and 0.58 in every 1,000 females.¹ Prognosis in relation to all-

31 Oct 2019

Dr. Chan, Wai-Kwong Andy

Specialist in Cardiology

ESC 2020

29 August - 1 September 2020 |

Virtual

More than glycated hemoglobin: Dapagliflozin preserves cardiorenal functions in patients with type 2 diabetes mellitus

CARDIOLOGY DIABETES & ENDOCRINOLOGY

21 Sep 2021

Professor Jonathan Shaw

Deputy Director,
Clinical and Population Health,
Baker Heart and Diabetes Institute,
Melbourne, Australia

Evolocumab greatly reduces low-density lipoprotein cholesterol levels in familial hypercholesterolemia: A local case review

Patients with familial hypercholesterolemia (FH) have an elevated low-density lipoprotein cholesterol (LDL-C) level, which translates into a higher risk of cardiovascular events.¹ Although maximum standard treatment of statins and ezetimibe in FH patients helps reduce the LDL-C level by at

30 Oct 2020

Prof. Brian Tomlinson

Faculty of Medicine,
Macau University of Science and Technology

High prevalence of thrombotic complications found in ICU-admitted COVID-19 patients, systematic screening warranted

Ever since the report of the very first case of coronavirus disease 2019 (COVID-19) in Wuhan back in December 2019, increasing evidence indicates that COVID-19 is associated with a high thrombotic risk.1,2 While the underlying mechanism of thrombus formation among COVID-19 patients had been well-inv

28 Jun 2021

Latest guideline addresses the gap in managing adult stage 1 hypertension with a low 10-year ASCVD risk

The 2017 Hypertension Clinical Practice Guideline issued by the American College of Cardiology/American Heart Association (ACC/AHA) Task Force outlined the general blood pressure (BP) management approach to adults with stage 1 hypertension and a 10-year risk for atherosclerotic cardiovascular diseas

28 Jun 2021

ONCOLOGY CARDIOLOGY NEUROLOGY RESPIROLOGY DIABETES & ENDOCRINOLOGY

Strategy to prevent and control NCDs in Hong Kong by 2025

30 Aug 2019

Lecture: Changing the trajectory of heart failure - To help your patients endure

Opening & discussion Heart failure - Current status in Hong Kong Changing the course of heart failure Hospitalisation and mortality in patients with heart failure treated with sacubitril/valsartan vs. enalapril - What does the real-world evidence show us?

02 Dec 2020